Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 9/20 | 0.68 |
| ▸ | HSD17B2 | P37059 | 9/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | KIF11 | P52732 | 3/20 | 0.63 |
| ▸ | AGXT | P21549 | 1/20 | 0.56 |
| ▸ | AR | P10275 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 3/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1029849 | 0.86 | HSD17B1 (0.58) | HSD17B1HSD17B2CYP3A4CYP2C9KIF11 | |
| SCHEMBL26821713 | 0.85 | KIF11 (0.73) | KIF11AGXTESR1MEN1KMT2A | |
| SCHEMBL7898375 | 0.82 | HSD17B1 (1.00) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL6068041 | 0.81 | KIF11 (0.71) | KIF11NPC1RAB9A | |
| SCHEMBL16068255 | 0.81 | KIF11 (0.67) | KIF11AGXTDHODH | |
| SCHEMBL322980 | 0.80 | KIF11 (0.63) | HSD17B1HSD17B2CYP3A4CYP2C9KIF11 | |
| SCHEMBL4671855 | 0.80 | HSD17B1 (0.68) | HSD17B1HSD17B2CYP3A4CYP2C9AR | |
| SCHEMBL4291389 | 0.80 | HSD17B1 (0.68) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL8050006 | 0.80 | HSD17B1 (0.94) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL22693261 | 0.78 | ESR1 (0.67) | HSD17B1HSD17B2CYP3A4CYP2C9KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081946-A2 | ADENOSINE DERIVATIVES FOR THE TREATMENT OF PAIN | Biovitrum AB (publ) (SE) | 2009-07-29 | — | — | EP | claimed |
| CN-101479289-A | Adenosine derivatives for the treatment of pain | BIOVITRUM AB PUBL (SE) | 2009-07-08 | — | — | CN | claimed |
| WO-2008000745-A2 | ADENOSINE DERIVATIVES FOR THE TREATMENT OF PAIN | BIOVITRUM AB (PUBL) (SE) | 2008-01-03 | — | — | WO | claimed |
| EP-3865472-B1 | THROMBOXANE RECEPTOR ANTAGONISTS | ATXA THERAPEUTICS LTD (IE) | 2024-06-12 | — | — | EP | disclosed |
| EP-3865472-A1 | THROMBOXANE RECEPTOR ANTAGONISTS | ATXA Therapeutics Limited (IE) | 2021-08-18 | — | — | EP | disclosed |
| EP-3865472-A1 | THROMBOXANE RECEPTOR ANTAGONISTS | ATXA Therapeutics Limited (IE) | 2021-08-18 | — | — | EP | disclosed |
| US-10966994-B2 | Thromboxane receptor antagonists | ATXA THERAPEUTICS LIMITED (IE) | 2021-04-06 | — | — | US | disclosed |
| US-10966994-B2 | Thromboxane receptor antagonists | ATXA THERAPEUTICS LIMITED (IE) | 2021-04-06 | — | — | US | disclosed |
| EP-3310756-B1 | THROMBOXANE RECEPTOR ANTAGONISTS | ATXA THERAPEUTICS LTD (IE) | 2020-12-09 | — | — | EP | disclosed |
| US-20190336513-A1 | THROMBOXANE RECEPTOR ANTAGONISTS | ATXA THERAPEUTICS LIMITED (IE) | 2019-11-07 | — | — | US | disclosed |
| US-10357504-B2 | Thromboxane receptor antagonists | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2019-07-23 | — | — | US | disclosed |
| US-20080027081-A1 | Therapeutic compounds | BIOVITRUM AB (PUBL) | 2008-01-31 | — | — | US | disclosed |
| US-20080027081-A1 | Therapeutic compounds | BIOVITRUM AB (PUBL) | 2008-01-31 | — | — | US | disclosed |
| US-20080027081-A1 | Therapeutic compounds | BIOVITRUM AB (PUBL) | 2008-01-31 | — | — | US | disclosed |
| WO-2008000743-A2 | NOVEL 2',3'-METHYLIDENE ACETYL ADENOSINE PRODRUGS FOR USE AS PRODRUGS FOR ADENOSINE RECEPTOR AGONISTS | BIOVITRUM AB (PUBL) (SE) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008000745-A2 | ADENOSINE DERIVATIVES FOR THE TREATMENT OF PAIN | BIOVITRUM AB (PUBL) (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20070185156-A1 | 8-Azabicyclo[3.2.1]octane derivatives | N.V. ORGANON (NL) | 2007-08-09 | — | — | US | disclosed |
| WO-2007063071-A1 | 8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | N.V. ORGANON (NL) | 2007-06-07 | — | — | WO | disclosed |
| US-7064144-B2 | Imidazole derivatives as adenosine deaminase inhibitors | ASTELLAS PHARMA INC. (JP) | 2006-06-20 | — | — | US | disclosed |
| US-20040236114-A1 | Imidazole derivatives as adenosine deaminase inhibitors | ASTELLAS PHARMA INC. (JP) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10966994-B2 | Thromboxane receptor antagonists | TBXA2R, TBXAS1, PTGIR | HSD17B1 2031/4885HSD17B2 1597/4885CYP3A4 1009/4885 |
| US-20190336513-A1 | THROMBOXANE RECEPTOR ANTAGONISTS | TBXA2R, PTGER2, PTGER1 | HSD17B1 1247/4885HSD17B2 820/4885CYP3A4 518/4885 |
| US-20040236114-A1 | Imidazole derivatives as adenosine deaminase inhibitors | ADA, ADAR, IMPDH1 | HSD17B1 362/4885HSD17B2 441/4885CYP3A4 311/4885 |
| US-20080027081-A1 | Therapeutic compounds | ADORA2A, ADORA3, ADORA2B | HSD17B1 3185/4885HSD17B2 2948/4885CYP3A4 767/4885 |
| US-10357504-B2 | Thromboxane receptor antagonists | TBXA2R, PTGER2, PTGER1 | HSD17B1 1247/4885HSD17B2 820/4885CYP3A4 518/4885 |
| US-20070185156-A1 | 8-Azabicyclo[3.2.1]octane derivatives | SLC22A8, SLCO1B3, SLCO1B1 | HSD17B1 1363/4885HSD17B2 1275/4885CYP3A4 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.